The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
GOTIC-018: Phase I, open-label, multicenter study to assess the safety of pre- and co-administration of ONO-4538 (nivolumab) with concurrent chemoradiation (CCRT) in patients (pts) with locally advanced cervical carcinoma (LACvCa).
 
Akira Yabuno
Honoraria - AstraZeneca Japan; Eisai; Takeda
 
Kazuto Nakamura
No Relationships to Disclose
 
Toyomi Satoh
Consulting or Advisory Role - AstraZeneca Japan
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Mochida Pharmaceutical Co. Ltd.; Takeda
Research Funding - Japan Agency for Medical Research and Development; Japan Society for the Promotion of Science
 
Hiroyuki Fujiwara
Honoraria - AstraZeneca Japan; Bayer; Chugai Pharma; Daiichi Sankyo; Mochida Pharmaceutical Co. Ltd.; MSD; Takeda; TERUMO
 
Akira Kurosaki
No Relationships to Disclose
 
Soichi Yamashita
No Relationships to Disclose
 
Toshihiro Misumi
Speakers' Bureau - AstraZeneca; Chugai Pharma
 
Shin-ei Noda
No Relationships to Disclose
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; MSD K.K; Takeda
Consulting or Advisory Role - Kaken Pharmaceutical; MSD K.K
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical